Objectives. To detect decreases in anogenital warts (AGW) among sex and age groups
likely to be affected by human papillomavirus vaccination. Methods. We estimated annual …

Background. Human papillomavirus (HPV) vaccination targeting females aged 12–13 years
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …

A consensus process was undertaken to describe and evaluate current information and
practice regarding the diagnosis, treatment, and evaluation of patients with external genital …

Background: The burden of anogenital warts will be a determining factor when making
decisions about the type of human papillomavirus (HPV) vaccine to be used (bivalent or …

BACKGROUND Typically occurring on the external genitalia, anogenital warts (AGWs) are
benign epithelial skin lesions caused by human papillomavirus infection. AGWs are usually …

The prevalence of genital warts (GW) and self-reported human papillomavirus (HPV) as well
as disease-related psychosocial impact among male and female patients aged 18–60 years …

Background. Genital warts is a common sexually transmitted disease treated by a variety of
medical specialists. Standard therapies offer symptomatic relief but cannot ensure lasting …

Genital warts affect 1% of the sexually active US population and are commonly seen in
primary care. Human papillomavirus types 6 and 11 are responsible for most genital warts …

In this Review, we describe the recent epidemiology of genital warts and postulate what the
future may hold as a result of the introduction of the quadrivalent human papillomavirus …

Because of the rapid development of genital warts (GW) after infection, monitoring GW
trends may provide early evidence of population-level human papillomavirus (HPV) vaccine …